Intellectus Partners LLC Buys New Position in Amgen Inc. (NASDAQ:AMGN)

Intellectus Partners LLC purchased a new position in Amgen Inc. (NASDAQ:AMGN) during the 4th quarter, HoldingsChannel reports. The firm purchased 997 shares of the medical research company’s stock, valued at approximately $260,000.

Other large investors also recently modified their holdings of the company. Swedbank AB increased its holdings in shares of Amgen by 1.1% during the 3rd quarter. Swedbank AB now owns 538,899 shares of the medical research company’s stock worth $173,639,000 after purchasing an additional 5,751 shares during the period. Capital Performance Advisors LLP acquired a new stake in Amgen during the third quarter worth about $25,000. Leavell Investment Management Inc. increased its stake in Amgen by 42.8% during the third quarter. Leavell Investment Management Inc. now owns 17,756 shares of the medical research company’s stock valued at $5,721,000 after acquiring an additional 5,325 shares during the period. CWA Asset Management Group LLC acquired a new position in Amgen in the 3rd quarter valued at approximately $1,719,000. Finally, Windward Capital Management Co. CA lifted its position in shares of Amgen by 2.6% in the 3rd quarter. Windward Capital Management Co. CA now owns 22,239 shares of the medical research company’s stock worth $7,166,000 after acquiring an additional 556 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Trading Up 2.2 %

Shares of NASDAQ AMGN opened at $324.86 on Friday. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The company has a 50-day moving average of $286.14 and a two-hundred day moving average of $299.69. The company has a market cap of $174.52 billion, a PE ratio of 43.03, a P/E/G ratio of 2.63 and a beta of 0.53.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, equities analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be given a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 2.93%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s dividend payout ratio is 126.09%.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on AMGN shares. Piper Sandler upped their target price on Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Jefferies Financial Group reaffirmed a “buy” rating and set a $380.00 price objective on shares of Amgen in a report on Tuesday, November 12th. StockNews.com cut shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Redburn Partners cut their price target on shares of Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Finally, William Blair reaffirmed an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $314.95.

Insider Buying and Selling

In related news, EVP David M. Reese sold 25,225 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $304.44, for a total value of $7,679,499.00. Following the sale, the executive vice president now directly owns 36,922 shares in the company, valued at $11,240,533.68. This trade represents a 40.59 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at $2,195,228.70. The trade was a 18.06 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 69,341 shares of company stock valued at $20,644,335 over the last ninety days. Insiders own 0.69% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.